Jacobus elected to give the drug away to this subset of LEMS patients, and did so for about twenty years.[18][19][20] Doctors at the Assistance Publique – Hôpitaux de Paris had created a phosphate salt of 3,4-DAP (3,4-DAPP), and obtained an orphan designation for it in Europe in 2002.[21] The hospital licensed the intellectual property on the phosphate form to the French biopharma company OPI, which was acquired by EUSA Pharma in 2007,[22] and the orphan application was transferred to EUSA in 2008.[21] In 2008 EUSA submitted an application for approval to market the phosphate form to the European Medicines Agency under the brand name Zenas.[23] EUSA, through a vehicle called Huxley Pharmaceuticals, sold the rights to 3,4-DAPP to BioMarin in 2009,[24] the same year that 3,4-DAPP was approved in Europe under the new name Firdapse.[21] The licensing of Firdapse in 2010 in Europe led to a sharp increase in price for the drug.